2022 World Conference on Lung Cancer (ePosters)-EP08.02-100. Combination of Bevacizumab and Continuation of EGFR-TKIs in NSCLC Patients beyond Gradual Progression

EP08.02-100. Combination of Bevacizumab and Continuation of EGFR-TKIs in NSCLC Patients beyond Gradual Progression

Pdf Summary

This study aimed to investigate the potential benefits of combining bevacizumab and EGFR-TKIs in NSCLC patients who had gradual progression. The data of 48 patients who received this combination therapy after gradual progression were analyzed. The results showed that the median post progression survival (PPS) was 11.4 months for all patients included in the study. The overall response rate (ORR) was 8.3% and the disease control rate (DCR) was 86.1%. Univariate Cox analysis revealed that age, gender, and EGFR exon19 deletion mutation were associated with longer PPS. Multivariate Cox analysis indicated that age and EGFR exon19 deletion mutation were independently associated with longer PPS. <br /><br />These findings suggest that continuation of EGFR-TKI with the combination of bevacizumab is a reasonable treatment strategy for NSCLC patients who have gradual progression after previous TKI treatment. Younger patients with EGFR exon19 deletion mutation may benefit more from this combination therapy. <br /><br />Overall, this study provides evidence for the potential efficacy of combining bevacizumab and EGFR-TKIs in NSCLC patients beyond gradual progression. Further research and clinical trials are warranted to validate these findings and optimize treatment strategies for this patient population.

Asset Subtitle

Ziyi Xu

Meta Tag

Speaker Ziyi Xu

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

bevacizumab

EGFR-TKIs

NSCLC

gradual progression

combination therapy

post progression survival

overall response rate

disease control rate

EGFR exon19 deletion mutation

treatment strategy